CytoDyn’s COVID-19 Long-Hauler’s Trial Closed as Enrollment
VANCOUVER, Wash., April 8, 2021 (GLOBE NEWSWIRE) - CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Firm"), a late-stage biotechnology firm creating Leronlimab (PRO 140), a CCR5 antagonist with potential a number of therapeutic…